Andreas Münch Selected Research

Therapeutics

1/2021	Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.
11/2019	Single-centre experience with anti-tumour necrosis factor treatment in budesonide-refractory microscopic colitis patients.
3/2019	Vedolizumab in Refractory Microscopic Colitis: An International Case Series.
12/2018	Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
1/2016	Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.
2/2010	Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Münch Research Topics

Disease

11	Collagenous Colitis 02/2024 - 03/2009
7	Microscopic Colitis 03/2024 - 03/2019
4	Lymphocytic Colitis 01/2020 - 01/2015
4	Inflammation (Inflammations) 01/2020 - 10/2007
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 04/2016
2	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 10/2021 - 01/2020
2	Necrosis 11/2019 - 03/2019
1	Diarrhea 01/2023
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Ulcerative Colitis 01/2021
1	Rupture 01/2019
1	Abdominal Pain (Pain, Abdominal) 04/2016
1	Drug-Related Side Effects and Adverse Reactions 01/2016
1	Critical Illness (Critically Ill) 10/2014
1	Vitamin D Deficiency 10/2014
1	Hemorrhage 02/2010

Drug/Important Bio-Agent (IBA)

11	Budesonide (Pulmicort)FDA LinkGeneric 01/2022 - 03/2009
4	CollagenIBA 01/2020 - 01/2015
4	Methotrexate (Mexate)FDA LinkGeneric 03/2019 - 01/2012
3	Bile Acids and Salts (Bile Acids)IBA 01/2023 - 10/2007
3	Adalimumab (Humira)FDA Link 11/2019 - 01/2012
2	RNA (Ribonucleic Acid)IBA 02/2024 - 01/2021
2	Loperamide (Imodium)FDA LinkGeneric 01/2023 - 05/2015
2	Phenobarbital (Luminal)FDA Link 01/2022 - 05/2015
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 10/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 03/2024
1	Opioid Receptors (Opioid Receptor)IBA 01/2023
1	ElectrolytesIBA 01/2023
1	OpiumIBA 01/2023
1	Lipocalin-2IBA 10/2021
1	Immunologic Factors (Immunomodulators)IBA 02/2021
1	Aquaporins (Water Channels)IBA 07/2020
1	aquaporin 8IBA 07/2020
1	Factor VII (Proconvertin)IBA 11/2019
1	Infliximab (Remicade)FDA Link 11/2019
1	vedolizumabIBA 03/2019
1	Azathioprine (Imuran)FDA LinkGeneric 03/2019
1	PolymersIBA 01/2019
1	Mesalamine (Mesalazine)FDA LinkGeneric 12/2018
1	Capsules (Microcapsules)IBA 01/2016
1	CytokinesIBA 05/2015
1	Cholestyramine Resin (Questran)FDA LinkGeneric 05/2015
1	Cholecalciferol (Vitamin D3)FDA Link 10/2014
1	Vitamin D FDA LinkGeneric 10/2014
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 02/2010
1	Clopidogrel (Plavix)FDA Link 02/2010
1	AntigensIBA 10/2007

Therapy/Procedure

6	Therapeutics 01/2021 - 02/2010
1	Length of Stay 10/2014
1	Operative Surgical Procedures 02/2010